ONCO TEAM DIAGNOSTIC

ONCO TEAM DIAGNOSTIC

ONCO TEAM SPECIALISTS The team at ONCO TEAM has 23 specialists: o 11 general pathology seniors: - 8 PhD (1 PhD on lung tumors pathology) o 3 general pathology specialists; o 2 dermopathology seniors; o 5 biologists: - 1 PhD in molecular biology; - 2 PhD students; o 5 technicians (laboratory medical assistants)

ONCO TEAM LABORATORY EQUIPMENT ONCO TEAM pathology lab is 95% automated with latest generation equipment purchased from the following companies: THERMO, LEICA, VENTANA, ROCHE and ABBOTT MOLECULAR: - Automated line equipment from THERMO (cryostat, tissue processor, embedding station, microtome, slide steiner, coverslipper) and from LEICA (tissue processor, embedding station, microtome, slide steiner) - 3 immnohistochemistry automated stations: - Benchmark Ventana ULTRA; - Benchmark Ventana XT; - BOND III- Leica. - ThermoBrite Hybridisation Station Abbott Molecular

Tissue processor Excelsior (Thermo) Work Station (Thermo) Tissue embedding stations (Leica and Thermo)

Slide stainer (Gemini) Microtome

ClearVue Coverslipper

IMMUNOHISTICHEMISTRY Benchmark Ventana ULTRA Benchmark Special Stains system Benchmark Ventana XT

IMMUNOHISTICHEMISTRY BOND III Leica

ThermoBrite hybridization

MICROSCOPY ROOM

KEY INDICATORS Increase in the number of patients Diversification and modernization of medical services Increase of the investment in the laboratory equipment Innovation

INCREASE IN THE NUMBER OF PATIENTS Evolution of the number of patients number of patients annually 14000 12000 10000 8000 6000 4000 2000 2385 6470 4805 9249 12382 0 2013 (8 months) 2014 2015 2016 2017 (10 months)

DIVERSIFICATION AND MODERNIZATION OF MEDICAL SERVICES 2013 Histopathology and manual IHC; Chromogenic in situ hybridization (CISH) for HER2neu; 3 technicians and 4 pathologists; 2014 40% of the IHC comprised automated techniques; Introducing fluorescence in situ hybridization (FISH) technique in soft tissue sarcomas (STS) and HER2neu; Introducing molecular biology techniques (KRAS and NRAS RFLP; EGFR PCR revers hybridization on strips);

DIVERSIFICATION AND MODERNIZATION OF MEDICAL SERVICES 2015 Increment of sample processing quality by the acquisition of a tissue processor (Excelsior AS) and Gemini AS Slide Stainer; 60% of the IHC comprised automated techniques (including ALK/ D5F3 clone for lung adenocarcinoma). 2016 80% of the IHC comprised automated techniques with two Ventana platforms (XT and Ultra) (including PDL1/SP263 clone for lung adenocarcinoma and other malignancies). For molecular biology the acquisition of Cobas Z 480 PCR platform Introducing molecular biology techniques (KRAS, NRAS, EGFR, BRAF Real Time PCR) for paraffin embedded tissue

DIVERSIFICATION AND MODERNIZATION OF MEDICAL SERVICES 2017 90% of the IHC comprised automated techniques - two Ventana platforms (XT and Ultra) and Bond III platform; For molecular biology the increment of test types on Cobas Z 480 PCR platform, by introducing the test on circulatory tumor cells DNA; 16 pathologists, 5 biologists, 5 technicians.

QUALITY ASSESSMENT Our company has a constant interest in increasing the quality. We have multiple yearly contracts with Labquality Finland (3x general histopathology-interpretation, 2x special stains, 3 x IHC, each of 5 antibodies/pathology) We also required IHC and molecular biology controls from the European Society of Pathology LUNG - ESP Lung External Quality Assessment Scheme COLON ESP External Quality Assessment Scheme

QUALITY ASSESSMENT Oncoteam is accredited for: ISO 15189 Standards: For Medical and Clinical Laboratories ISO 9001 - Quality management

INNOVATION The pathologists and some of the biologists from ONCO TEAM have years of experience in the research field (from the period they activated in Victor Babes National Institute and the University of Bucharest) 23 national research projects, 1 POSCCE and 1 POSDRU Currently Onco Team is involved in the project Liquid biopsy technology development for prognostics and therapy modulation in malignant epithelial cancers PN-III-P (national project) 2-2.1-PTE-2016-0149

Liquid biopsy technology development for prognostics and therapy modulation in malignant epithelial cancers (poster)pn-iii-p (national project) 2-2.1-PTE-2016-0149 la al 29-lea Congres European de Patologie 2-6 Septembrie 2017, Amsterdam Olanda

THE DYNAMIC OF BUSINESS INDICATORS 3500000 Evolution of key indicators 3000000 2500000 2000000 1500000 Profit Turnover investment 1000000 500000 0 2013 2014 2015 2016-500000

Thank you for your attention!